Short description
Day One Biopharmaceuticals develops targeted therapies to treat people with life-threatening diseases.
Description
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages. The company understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. They develop new therapies that meet the critical needs of people of all ages living with cancer starting from the biology of childhood cancer.
Day One Biopharmaceuticals also focuses its efforts to bring the best medicines to families receiving the life-altering news of a new cancer diagnosis and the need for a treatment plan. It prioritizes programs that can be rapidly brought to market for both younger and older patients. The company's goal is to license and acquire the most promising products from research institutions as well as for biotechnology and pharmaceutical companies.
Last funding
Uh Ohhhh
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
South San Francisco, California, United States, North America
Founded on
November 1, 2018
Exited on
May 26, 2021
Went public on
May 26, 2021
Stock symbol
DAWN
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$7890 - 12340
Sign in for full access
Investors
Cannot Access, Noaccessforu, Noaccess, Cannot Access, Nopepepe, Noway Youcantaccess, Blurry Noaccess, Absolutely Noaccess, Noaccess, Cannot Access, Nopepepe
Sign in for full access
Founders
Julie Papanek Grant, Samuel Blackman